Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy

Journal of Medical Virology

Volumn 78, Issue 8, 2006, Pages 1131-1140

  Carcopino, X ^a,b,c   Henry, M ^a   Benmoura, D ^b   Fallabregues, A S ^b   Richet, H ^c   Boubli, L ^b   Tamalet, C ^a,c  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL NORD   (France)

^c CNRS   (France)

Author keywords

Cervical cancer; Human papillomavirus; Real time PCR; Viral load

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; COLPOSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VAGINA SMEAR; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CERVIX UTERI; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; VIRAL PROTEINS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 33745713010     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20673     Document Type: Article

References (35)

1. ACOG. 2003. Practice bulletin: Clinical management guidelines for obstetrician-gynecologists. Cervical cytology screening. Obstet Gynecol 102:417-427.
2. Beby-Defaux A, Bourgoin A, Ragot S, Battandier D, Lemasson JM, Renaud O, Bouguermouh S, Vienne Md Mde L, Agius G. 2004. Human papillomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security. J Med Virol 73:262-268.
3. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 87:796-802.
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. 2002. The causal relation between human Papilloma virus and cervical cancer. J Clin Pathol 55:244-265.
5. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J. 1995. Human papillomavirus testing in primary cervical screening. Lancet 345:1533-1536.
6. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362:1871-1876.
7. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 106:396-403.
8. Dillner J, Lehtinen M, Bjorge T, Luostarinen T, Youngman L, Jellum E, Koskela P, Gislefoss RE, Hallmans G, Paavonen J, Sapp M, Schiller JT, Hakulinen T, Thoresen S, Hakama M. 1997. Prospective sero epidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 89:1293-1299.
9. Ferlay J, Bray F, Pisani P, Parkin DM. 2004. Globocan 2002: Cancer incidence, mortality and prevalence worldwide [database on CD-ROM]. Lyon, France7 IARC Press; 2004 [IARC Cancerbase No. 5, version 2.0.].
10. Forslund O, Lindqvist P, Haadem K, Czegledy J, Hansson BG. 1997. HPV 16 DNA and mRNA in cervical brush samples quantified by PCR and microwell hybridization. J Virol Methods 69:209-222.
11. Gravitt PE, Peyton C, Wheeler C, Apple R, Higuchi R, Shah KV. 2003. Reproducibility of HPV 16 and HPV 18 viral load quantifying by using TaqMan real-time PCR assays. J Virol Methods 112:23-33.
12. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 8:3905-3910.
13. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. 1995. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87:1365-1371.
14. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervico vaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
15. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. 2000. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. Int J Cancer 87:221-227.
16. Josefsson A, Livak K, Gyllensten U. 1999. Detection and quantification of human papillomavirus by using the fluorescent 5′ exunuclease assay. J Clin Microbiol 37:490-496.
17. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, Melbye M, Adami HO, Gyllensten UB. 2000. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study. Lancet 355:2189-2193.
18. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ. 1996. Human papillomavirus-The most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 65:601-606.
19. Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB. 2004. DNA micro array format for detection and subtyping of human papillomavirus. J Clin Microbiol 42:2152-2160.
20. Lo KW, Yeung SW, Cheung TH, Siu NS, Kahn T, Wong YF. 2005. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: A study in Chinese population. J Clin Virol 34:76-80.
21. Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M. 2002. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 360:228-229.
22. Moberg M, Gustavsson I, Gyllensten U. 2003. Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol 41:3221-3228.
23. Moberg M, Gustavsson I, Gyllensten U. 2004. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 112:854-859.
24. Moberg M, Gustavsson I, Wilander E, Gyllensten U. 2005. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 92:891-894.
25. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518-527
26. Remmink AJ, Walboomers JM, Heimerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P. 1995. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 61:306-311.
27. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106-3114.
28. Swan DC, Tucker RA, Tortolero-Luna G, Mitchell MF, Wideroff L, Unger ER, Nisenbaum RA, Reeves WC, Icenogle JP. 1999. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol 37:1030-1034.
29. Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, Markowitz L, Unger ER. 2004. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis 189:46-50.
30. Van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 98:590-595.
31. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
32. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G, Dillner J. 1999. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 341:1633-1638.
33. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357:1831-1836.
34. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, Adami HO, Gyllensten UB, Melbye M. 2000. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: A nested case-control study. Lancet 355:2194-2198.
35. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, de Schipper FA, Meijer CJ. 2001. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 85:398-404.